Copyright © 2005, European Society of Cardiology
Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism
aDepartment of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
bDepartment of Internal Medicine and Molecular Science, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
cCardiovascular Division of Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
* Corresponding author. Tel.: +81 6 6833 5012x2225; fax: +81 6 6836 1120. Email address: kitakaze{at}zf6.so-net.ne.jp
Objective: Insulin resistance (IR) was reported to be associated with chronic heart failure (CHF). Adiponectin, an insulin-sensitizing hormone with anti-inflammatory activity, improves energy metabolism via AMP-activated protein kinase (AMPK). AMPK deficiency is associated with depressed cardiac function under stress conditions. However, it is not clear whether adiponectin plays an important role in CHF. We hypothesize that deficiency of adiponectin might result in deterioration of heart failure.
Methods: Using adiponectin null mice and their littermates, we examined the effects of adiponectin on LV pressure overload-induced cardiac hypertrophy and failure, and investigated the mechanisms involved.
Results: Three weeks after transverse aortic constriction (TAC), cardiac hypertrophy (evaluated from the heart-to-body weight ratio: 7.62 ± 0.27 in wild-type (WT) mice, 9.97 ± 1.13 in knockout (KO) mice, P<0.05) and pulmonary congestion (lung-to-body weight ratio: 9.05 ± 1.49 in WT mice, 14.95 ± 2.36 in KO mice, P<0.05) were significantly greater in adiponectin KO mice than WT mice. LV dimensions were also increased in KO mice. Compared with WT TAC mice, expression of AMPK
protein was lower, while IR was higher in KO TAC mice.
Conclusion: These findings indicate that adiponectin deficiency leads to progressive cardiac remodeling in pressure overloaded condition mediated via lowing AMPK signaling and impaired glucose metabolism.
KEYWORDS Adiponectin; Heart failure; Myocardial hypertrophy; Metabolic syndrome
Time for primary review 24 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Sulpice, B. Prunet-Marcassus, C. Molveaux, P. D. Cani, P.-A. Vitte, P. Graber, M. Dreano, and R. Burcelin An Adiponectin-Like Molecule with Antidiabetic Properties Endocrinology, October 1, 2009; 150(10): 4493 - 4501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tsukamoto, M. Fujita, M. Kato, S. Yamazaki, Y. Asano, A. Ogai, H. Okazaki, M. Asai, Y. Nagamachi, N. Maeda, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2070 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sasaki, H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, et al. Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase Circulation, May 19, 2009; 119(19): 2568 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, E. Gao, L. Tao, W. B. Lau, Y. Yuan, B. J. Goldstein, B. L. Lopez, T. A. Christopher, R. Tian, W. Koch, et al. AMP-Activated Protein Kinase Deficiency Enhances Myocardial Ischemia/Reperfusion Injury but Has Minimal Effect on the Antioxidant/Antinitrative Protection of Adiponectin Circulation, February 17, 2009; 119(6): 835 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Raher, H. B. Thibault, E. S. Buys, D. Kuruppu, N. Shimizu, A.-L. Brownell, S. L. Blake, J. Rieusset, M. Kaneki, G. Derumeaux, et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2495 - H2502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zhang, X. Hu, X. Xu, J. Fassett, G. Zhu, B. Viollet, W. Xu, B. Wiczer, D. A. Bernlohr, R. J. Bache, et al. AMP Activated Protein Kinase-{alpha}2 Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice Hypertension, November 1, 2008; 52(5): 918 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zamilpa and M. L. Lindsey AMP Activated Protein Kinase 2 Protection During Hypertension-Induced Hypertrophy: A Common Mediator in the Signaling Crossroads Hypertension, November 1, 2008; 52(5): 813 - 815. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart Cardiovasc Res, July 15, 2008; 79(2): 279 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Skurk, F. Wittchen, L. Suckau, H. Witt, M. Noutsias, H. Fechner, H.-P. Schultheiss, and W. Poller Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy Eur. Heart J., May 1, 2008; 29(9): 1168 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fujita, N. Maeda, M. Sonoda, K. Ohashi, T. Hibuse, H. Nishizawa, M. Nishida, A. Hiuge, A. Kurata, S. Kihara, et al. Adiponectin Protects Against Angiotensin II-Induced Cardiac Fibrosis Through Activation of PPAR-{alpha} Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 863 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanaka, T. Tsutamoto, H. Sakai, K. Nishiyama, M. Fujii, T. Yamamoto, and M. Horie Effect of atrial natriuretic peptide on adiponectin in patients with heart failure Eur J Heart Fail, April 1, 2008; 10(4): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Xu, E. D. Lekgabe, X.-M. Gao, Z. Ming, G. W. Tregear, A. M. Dart, R. A. D. Bathgate, C. S. Samuel, and X.-J. Du Endogenous Relaxin Does Not Affect Chronic Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis Endocrinology, February 1, 2008; 149(2): 476 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Duda, K. M. O'Shea, B. Lei, B. R. Barrows, A. M. Azimzadeh, T. E. McElfresh, B. D. Hoit, W. J. Kop, and W. C. Stanley Dietary supplementation with {omega}-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload Cardiovasc Res, November 1, 2007; 76(2): 303 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk, C. D.L. Folmes, and W. C. Stanley Cardiac Energy Metabolism in Obesity Circ. Res., August 17, 2007; 101(4): 335 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Palanivel, X. Fang, M. Park, M. Eguchi, S. Pallan, S. De Girolamo, Y. Liu, Y. Wang, A. Xu, and G. Sweeney Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes Cardiovasc Res, July 1, 2007; 75(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Shibata, K. Sato, M. Kumada, Y. Izumiya, M. Sonoda, S. Kihara, N. Ouchi, and K. Walsh Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment Cardiovasc Res, June 1, 2007; 74(3): 471 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mitsuhashi, H. Yatsuya, K. Tamakoshi, K. Matsushita, R. Otsuka, K. Wada, K. Sugiura, S. Takefuji, Y. Hotta, T. Kondo, et al. Adiponectin Level and Left Ventricular Hypertrophy in Japanese Men Hypertension, June 1, 2007; 49(6): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wiecek, M. Adamczak, and J. Chudek Adiponectin--an adipokine with unique metabolic properties Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Hopkins, N. Ouchi, R. Shibata, and K. Walsh Adiponectin actions in the cardiovascular system Cardiovasc Res, April 1, 2007; 74(1): 11 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arad, C. E. Seidman, and J.G. Seidman AMP-Activated Protein Kinase in the Heart: Role During Health and Disease Circ. Res., March 2, 2007; 100(4): 474 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. B. Dyck and G. D. Lopaschuk AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol., July 1, 2006; 574(1): 95 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ingelsson, U. Riserus, C. Berne, J. Frystyk, A. Flyvbjerg, T. Axelsson, P. Lundmark, and B. Zethelius Adiponectin and risk of congestive heart failure. JAMA, April 19, 2006; 295(15): 1772 - 1774. [Full Text] [PDF]
|
|
|
|
|
|
Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Piper and E. A. Martinson Cardiovascular Research speeds up-Even more Cardiovasc Res, March 1, 2006; 69(4): 773 - 776. [Full Text] [PDF]
|
|
|
|
|
|
E. Ingelsson, J. Sundstrom, J. Arnlov, B. Zethelius, and L. Lind Insulin Resistance and Congestive Heart Failure--Reply JAMA, November 23, 2005; 294(20): 2578 - 2578. [Full Text] [PDF]
|
|